Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
Humans
Female
Breast Neoplasms
/ drug therapy
Premenopause
Adult
Retrospective Studies
Receptor, ErbB-2
/ metabolism
Chemotherapy, Adjuvant
/ methods
Antineoplastic Agents, Hormonal
/ therapeutic use
Tamoxifen
/ therapeutic use
Aromatase Inhibitors
/ therapeutic use
Middle Aged
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Ovary
/ drug effects
HER2‐positive
adjuvant therapy
breast cancer
endocrine therapy
hormone receptor positive
premenopausal
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
20
04
2024
received:
01
02
2024
accepted:
08
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
ppublish
Résumé
The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit and clinical indications of ovarian suppression (OS) is poorly elucidated. We described real-world patterns surrounding choice of ET and clinicopathologic features which predicted treatment with OS in a contemporary cohort of premenopausal women with HR+/HER2+ BC. This retrospective analysis included premenopausal patients with nonmetastatic HR+/HER2+ BC from the CancerLinQ Discovery database from January 2010 to May 2020. Women were less than 50 years and received chemotherapy, anti-HER2 therapy, and ET. They were categorized into 1 of 4 groups based on type of ET prescribed at initiation: aromatase inhibitor (AI) + OS, OS, tamoxifen + OS, or tamoxifen. Multivariable logistic regression assessed associations between clinicopathologic features and OS use. Out of 360,540 patients with BC, 937 were included. The majority (n = 818, 87%) were prescribed tamoxifen, whereas 4 (0.4%), 50 (5.3%), and 65 (6.9%) received OS, tamoxifen + OS and AI + OS, respectively. No clinicopathologic features predicted OS use apart from age; patients <35 years were more likely to receive OS compared with those ≥35 years (odds ratio 2.33, p < 0.001). This is the first real-world study evaluating ET treatment patterns in HR+/HER2+ premenopausal BC. OS use was uncommon and the majority received tamoxifen as the preferred ET regardless of most clinicopathologic risk factors. Additional research is needed to optimize ET decisions in young women with this distinct BC subtype.
Sections du résumé
BACKGROUND
BACKGROUND
The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit and clinical indications of ovarian suppression (OS) is poorly elucidated. We described real-world patterns surrounding choice of ET and clinicopathologic features which predicted treatment with OS in a contemporary cohort of premenopausal women with HR+/HER2+ BC.
METHODS
METHODS
This retrospective analysis included premenopausal patients with nonmetastatic HR+/HER2+ BC from the CancerLinQ Discovery database from January 2010 to May 2020. Women were less than 50 years and received chemotherapy, anti-HER2 therapy, and ET. They were categorized into 1 of 4 groups based on type of ET prescribed at initiation: aromatase inhibitor (AI) + OS, OS, tamoxifen + OS, or tamoxifen. Multivariable logistic regression assessed associations between clinicopathologic features and OS use.
RESULTS
RESULTS
Out of 360,540 patients with BC, 937 were included. The majority (n = 818, 87%) were prescribed tamoxifen, whereas 4 (0.4%), 50 (5.3%), and 65 (6.9%) received OS, tamoxifen + OS and AI + OS, respectively. No clinicopathologic features predicted OS use apart from age; patients <35 years were more likely to receive OS compared with those ≥35 years (odds ratio 2.33, p < 0.001).
CONCLUSIONS
CONCLUSIONS
This is the first real-world study evaluating ET treatment patterns in HR+/HER2+ premenopausal BC. OS use was uncommon and the majority received tamoxifen as the preferred ET regardless of most clinicopathologic risk factors. Additional research is needed to optimize ET decisions in young women with this distinct BC subtype.
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Antineoplastic Agents, Hormonal
0
Tamoxifen
094ZI81Y45
ERBB2 protein, human
EC 2.7.10.1
Aromatase Inhibitors
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7317Informations de copyright
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
Références
Peleg Hasson S, Brezis MR, Shachar E, Shachar SS, Wolf I, Sonnenblick A. Adjuvant endocrine therapy in HER2‐positive breast cancer patients: systematic review and meta‐analysis. ESMO Open. 2021;6(2):100088.
Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone receptor/human epidermal growth factor receptor 2‐positive breast cancer: where we are now and where we are going. Cancer Treat Rev. 2016;46:20‐26.
Han Y, Wu Y, Xu H, Wang J, Xu B. The impact of hormone receptor on the clinical outcomes of HER2‐positive breast cancer: a population‐based study. Int J Clin Oncol. 2022;27(4):707‐716.
Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436‐446.
Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122‐137.
Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107‐118.
Pagani O, Walley BA, Fleming GF, et al. Adjuvant Exemestane with ovarian suppression in premenopausal breast cancer: long‐term follow‐up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41(7):1376‐1382.
Potter D, Brothers R, Kolacevski A, et al. Development of CancerLinQ, a health information learning platform from multiple electronic health record systems to support improved quality of care. JCO Clin Cancer Inform. 2020;4:929‐937.
Potter DM, Riffon MF, Manning B, et al. Summary of the 12 Most common cancers in the CancerLinQ discovery (CLQD) database. JCO Clin Cancer Inform. 2021;5:658‐667.
Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691‐722.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022 https://www.R‐project.org/. In
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor‐positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689‐1701.
Gray RBR, Braybrooke J, Clarke M, et al. Abstract 503: effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient‐level meta‐analysis of 14,993 pre‐menopausal women in 25 randomized trials. J Clin Oncol. 2023;41:503.
Dieci MV, Bisagni G, Bartolini S, et al. Type of adjuvant endocrine therapy and disease‐free survival in patients with early HR‐positive/HER2‐positive BC: analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer. 2023;9(1):6.
Lambertini M, Campbell C, Gelber RD, et al. Dissecting the effect of hormone receptor status in patients with HER2‐positive early breast cancer: exploratory analysis from the ALTTO (BIG 2‐06) randomized clinical trial. Breast Cancer Res Treat. 2019;177(1):103‐114.
Dackus GMHE, Jóźwiak K, Sonke GS, et al. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: a population‐based cohort study. Eur J Cancer. 2018;90:92‐101.
van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three‐year follow‐up of Neoadjuvant chemotherapy with or without Anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2‐positive breast cancer: a secondary analysis of the TRAIN‐2 randomized, phase 3 trial. JAMA Oncol. 2021;7(7):978‐984.